With our progress on ARRY-614 for myelodysplastic syndromes and 520 for multiple myeloma, we see a clear internal focus on HemOnc space. We believe that focusing our internal programs will in fact maximize our likelihood for success.
Now taking a quick look back, Array has an incredible legacy in terms to developing great molecule, and its history Array has filed INDs on 18 molecules which remarkable is that 15 of them are still in human development and full 10 of those are currently in Phase 2. One thing to create a molecule it's something very different to have that molecule survive into Phase 2 and we have 10 of those, 7 are partnered with some of the finest companies in the industry such as AstraZeneca, Novartis, Genentech, Amgen, Celgene and others. And we are very excited about those partnerships and they are progressing well.
We have also been able to raise non-dilutive capital very effectively, and just in the past couple of years we have raised about $170 million from high value licensing partnerships. As recently as August of last year we announced the deal with Genentech on a pre-clinical Chk-1 program that included a $28 million upfront payment nearly 700 million in potential milestones and the potential for double-digit royalties. And these types of turns have not been unusual for Array assets. In fact we add up all of the potential milestones related to our partner portfolio a total of $3.4 billion and this is before royalties kick in. And there are additional assets that we will be looking to partner between now and the end of calendar year 2013.
So, currently we have about 90 million in cash as of the end of June and that should sustain us for a good period of time especially as we expect to do more partnering. The next 12 months is going to be very exciting and I will be reviewing some of the key catalyst with you today.Read the rest of this transcript for free on seekingalpha.com
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV